Larson Financial Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Larson Financial Group's CORT Position: Q3 2026 in Review
Larson Financial Group increased its Corcept Therapeutics (CORT) stake by 8.3% in Q3 2026, buying an estimated $753 and bringing the position to 91 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.
Larson Financial Group first reported a position in CORT in Q2 2024 and has held it in 10 quarters since. The position peaked at $38.3K in Q3 2025. 502 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Larson Financial Group held 91 shares of Corcept Therapeutics worth $10.5K as of Q3 2026.
- Larson Financial Group bought 7 Corcept Therapeutics shares in Q3 2026, an estimated $753.
- Corcept Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2487 holding.
- Larson Financial Group first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 10 quarters since.
- Larson Financial Group's Corcept Therapeutics position peaked at $38.3K in Q3 2025.
- 502 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.